McLean Laboratory Publications

• Frederick PJ, Seshadri M, Zsiros E, McLean K. Reflections on Medical Trainee Unions and Health Care Systems. JAMA. 2025 Nov 4;334(17):1511-1512. doi: 10.1001/jama.2025.14762. PMID: 40996742.
• Duhon AA, McLean K. Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates. Cancer Heterog Plast. 2025;2(4):10.47248/chp2502040017. doi: 10.47248/chp2502040017. Epub 2025 Oct 15. PMID: 41334034; PMCID: PMC12668522.
• Nakatsuka E, Tan L, Cunneen B, Foster C, Lei YL, McLean K. Characterization of DNA damage repair pathway utilization in high-grade serous ovarian cancers yields rational therapeutic approaches. Transl Oncol. 2024 Dec;50:102119. doi: 10.1016/j.tranon.2024.102119. Epub 2024 Sep 12. PMID: 39270525; PMCID: PMC11416511.
• Tondo-Steele K, McLean K. The "Sweet Spot" of Targeting Tumor Metabolism in Ovarian Cancers. Cancers (Basel). 2022 Sep 27;14(19). doi: 10.3390/cancers14194696. Review. PubMed PMID: 36230617; PubMed Central PMCID: PMC9562887.
• Tan L, Tondo-Steele K, Foster C, McIlwain C, Bolland DE, Crawford HC, Sciallis A, McLean K. Inhibition of Tumor Microenvironment Cytokine Signaling Sensitizes Ovarian Cancer Cells to Antiestrogen Therapy. Cancers (Basel). 2022 Sep 26;14(19). doi: 10.3390/cancers14194675. PubMed PMID: 36230597; PubMed Central PMCID: PMC9564160.
• Coffman LG, Orellana TJ, Liu T, Frisbie LG, Normolle D, Griffith K, Uppal S, McLean K, Berger J, Boisen M, Courtney-Brooks M, Edwards RP, Lesnock J, Mahdi H, Olawaiye A, Sukumvanich P, Taylor SE, Buckanovich R. Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer. JCI Insight. 2022 Sep 22;7(18). doi: 10.1172/jci.insight.160573. PubMed PMID: 35972817; PubMed Central PMCID: PMC9675476.
• Armstrong DK, Alvarez RD, Backes FJ, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Chitiyo VC, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA III, Leiserowitz G, Liu J, Martin L, Matei D, McHale M, McLean K, Miller DS, Percac-Lima S, Remmenga SW, Schorge J, Stewart D, Thaker PH, Vargas R, Hendrickson AW, Werner TL, Zsiros E, Dwyer MA, Hang L. NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. J Natl Compr Canc Netw. 2022 Sep;20(9):972-980. doi: 10.6004/jnccn.2022.0047. PubMed PMID: 36075393.
• Bell SG, Dalton L, McNeish BL, Fang F, Henry NL, Kidwell KM, McLean K. Aromatase inhibitor use, side effects and discontinuation rates in gynecologic oncology patients. Gynecol Oncol. 2020 Nov;159(2):509-514. doi: 10.1016/j.ygyno.2020.08.015. Epub 2020 Aug 23. PubMed PMID: 32847676; PubMed Central PMCID: PMC8036903.
• McLean K, Tan L, Bolland DE, Coffman LG, Peterson LF, Talpaz M, Neamati N, Buckanovich RJ. Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth. Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. Epub 2018 Oct 10. PubMed PMID: 30305729; PubMed Central PMCID: PMC6374186.
• Hacker KE, Bolland DE, Tan L, Saha AK, Niknafs YS, Markovitz DM, McLean K. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival. Neoplasia. 2018 Dec;20(12):1209-1218. doi: 10.1016/j.neo.2018.10.005. Epub 2018 Nov 6. PubMed PMID: 30412857; PubMed Central PMCID: PMC6226625.
• Andersen CL, Sikora MJ, Boisen MM, Ma T, Christie A, Tseng G, Park Y, Luthra S, Chandran U, Haluska P, Mantia-Smaldone GM, Odunsi K, McLean K, Lee AV, Elishaev E, Edwards RP, Oesterreich S. Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. Clin Cancer Res. 2017 Jul 15;23(14):3802-3812. doi: 10.1158/1078-0432.CCR-16-1501. Epub 2017 Jan 10. PubMed PMID: 28073843; PubMed Central PMCID: PMC5503796.
• Brackmann M, Reynolds RK, Uppal S, McLean K. Association of a Biweekly Research Workgroup With Enhanced Resident Research Productivity. Obstet Gynecol. 2016 Sep;128(3):617-620. doi: 10.1097/AOG.0000000000001574. PubMed PMID: 27500350.

View all publications on PubMed